Renal News: Breaking Renal News, Comments and Articles. - Page: 3

Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage Strengths

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 8,440,703 (“the ‘703 patent”) entitled “Methods of Using Sustained Release Aminopyridine Compositions.” The ‘703 patent includes claims directed to methods of improving lower extremity function and...

Rosetta Genomics Announces Credentialing Agreement with Prime Health Services for miRview mets2

PHILADELPHIA and REHOVOT, Israel, May 20, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed a credentialing agreement with Prime Health Services, Inc. (Prime Health), a managed care company that offers a full spectrum of services, including a Preferred...

Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes

SAN DIEGO, May 20, 2013 /PRNewswire/ -- Enrollment of patients with Type 2 diabetes is underway in Elcelyx Therapeutics' Phase 2b dose-finding clinical trial of product candidate NewMet™, a delayed-release formulation of generic metformin, the foundational treatment for Type 2 diabetes. Elcelyx expects to complete enrollment of 240 patients in the multicenter U.S. program in June. Results of...

TRACON Pharmaceuticals Announces TRC105 Clinical Trials, Abstract Presentations at 2013 ASCO Annual Meeting

SAN DIEGO, May 20, 2013 /PRNewswire/ -- TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced multiple clinical investigations for TRC105 and the presentation of two abstracts at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), held May 31 to June 4 in Chicago. TRC105, a novel monoclonal...

AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy

NORTH CHICAGO, Ill., May 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease (CKD) and...

Fastcare Advises on How to Prevent a UTI

Miami, FL (PRWEB) May 20, 2013 Fastcare Miami Beach clinic advises patients to treat a possible urinary tract infection (UTI) within its first symptoms, as if not treated, it may involve the ureter and the kidneys resulting in a more serious inf...

US Drug Watchdog Now Urges Transvaginal Mesh Failure Victims With Erosion To Call Them For The Names And Contacts Of The Best Women Attorneys

The US Drug Watchdog is now assuring all victims of a transvaginal mesh failure, if they call them, they will be provided with the names, and contacts of national caliber women attorneys, especially if the failure involves erosion, or other severe medical complications. For more information victims of a transvaginal mesh failure involving severe medical complications are urged to contact the US Dr...

New Drug Combinations Block Kidney Cancer in Culture and Mouse Models

Drugs that block the activity of the enzyme Stearoyl-CoA desaturase-1 repress the growth of kidney cancer cells in culture and...

Aveo Pharmaceuticals, Inc. Sued by Investor

SAN DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP announce that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) securities has filed a complaint in the U.S. District Court for the District of Massachusetts.  The complaint alleges that Aveo and certain of its officers violated the Securities Exchange Act of...

TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map

BOSTON, May 17, 2013 /PRNewswire/ -- TechAtlas Group has announced the release of the latest update for their competitive landscape map for the Chronic Kidney Disease (CKD) market. This particular landscape highlights over 90 international companies with drugs and devices currently on the market and in development addressing CKD and its sequelae. (Logo:  http://photos.prnewswire.com/pr...

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm

NEW YORK, May 18, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ: AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses on whether the Company and its executives violated federal securities laws by issuing m...

Final STRATO Clinical Study Data Demonstrates Potential for LCP-Tacro™ to Improve Tacrolimus-Induced Tremors

HORSHOLM, Denmark, May 20, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the STRATO study demonstrates the potential for LCP-Tacro™ to improve tacrolimus-induced tremors in stable kidney transplant patients.  The study, Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO™ (STRATO) clinical trial, was presented a...

Structural basis for alternating access of a eukaryotic calcium/proton exchanger

Eukaryotic Ca2+ regulation involves sequestration into intracellular organelles, and expeditious Ca2+ release into the cytosol is a hallmark of key signalling transduction pathways. Bulk removal of Ca2+ after such signalling events is accomplished by...

Rockwell Medical Closes $40.3 Million Public Offering of Common Stock

WIXOM, MI -- (Marketwired) -- 05/20/13 -- Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today the closing of the sale of 13,196,721 common shares, includ...

Rockwell Medical Presents PRIME Study Results at the 50th ERA-EDTA Meeting in Istanbul, Turkey

WIXOM, MI -- (Marketwired) -- 05/20/13 -- Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today PRIME clinical study results for Soluble Ferric Pyrophosphate (SF...

BP Reductions With Renal Denervation Durable to 30 Months

New data confirm the long-term efficacy of renal denervation in patients with resistant hypertension. At 30 months, there was a sustained reduction in systolic blood pressure, but this is only the beginning in terms of understanding the potential of...

In Patients With Kidney Disease, LDL Cholesterol Is A Poor Marker Of Heart Health

Other measures are needed to assess patients' cardiovascular risks Among patients with chronic kidney disease, those with very low kidney function had a higher risk of having a heart attack than those with higher kidney function over a four-year...

Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation

The Firm is actively filing transvaginal mesh lawsuits on behalf of women who suffered serious complications, allegedly due to Ethicon Gynecare Pelvic Mesh Products. New York, New York (PRWEB) May 18, 2013 Transvaginal mesh lawsuits involving Ethicon Inc.’s Gynecare pelvic mesh products continue to move forward in a consolidated litigation underway in New Jersey’s Atlantic County Superior Cou...

Dr. Allen’s Device Reverses Prostate Enlargement without Side Effects in Contrast to BPH Laser Surgeries and TURP, Highlights Fine Treatment

BPH treatment with Dr. Allen’s Device terminates prostate enlargement at the capillary level without any side effects. While a new study suggests that laser therapy for BPH is equally safe and effective as the commonly used TURP, both of these surgical procedures frequently cause serious complications, states Fine Treatment. London, UK (PRWEB) May 18, 2013 When selecting a prostate enlargement...

Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome

The personal injury law firm of d’Oliveira & Associates has issued an infographic on Stevens Johnson Syndrome, which details potential causes and serious conditions that may result from the syndrome. (PRWEB) May 18, 2013 According to the the Stevens Johnson Syndrome Foundation, Stevens Johnson Syndrome (SJS), also known as Toxic Epidermal Necrolysis, is a severe allergic reaction usually to...

The Polycystic Liver: Webinar & Talk

Hamilton, Canada, May 18, 2013 --(PR.com)-- On May 26, the Hamilton Chapter of the PKD Foundation of Canada will host a webinar by Dr. Marie Hogan of the Mayo Clinic in Rochester, MN, followed by a talk by two-time liver transplant recipient Jan Robertson, Co-Founder of The PKD Foundation of Canada. “Polycystic Kidney Disease can affect multiple organs in a PKD patient and many individuals...

Why the Precautionary Principal is a Crock. Speed Matters when it comes to Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics

VACCINES Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics

Novartis drug Afinitor® significantly extended time without disease progression in women with HER2 positive advanced breast cancer

Novartis International AG / Novartis drug Afinitor® significantly extended time without disease progression in women with HER2 positive advanced breast cancer . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Everolimus plus trastuzumab and vinorelbine met primary endpoint of extending PFS compared to placebo plus trastu...

Public offering nets $18.8mm for [Cyclacel]

[Cyclacel Pharmaceuticals Inc.] (mainly cancer therapies; also has projects for kidney disease, diabetes, and HIV/AIDS) netted $18.8mm through public offering of 6.67mm common shares at $3 each. Proceeds will fund a Phase III trial of Cyclacel's sapa...

[Rockwell Medical] nets $38mm through FOPO

[Rockwell Medical Inc.] (end-stage renal and chronic kidney disease treatments) has netted $38mm through the follow-on public offering of 13.2mm common shares (including the overallotment) at $3.05. The money will be used for ongoing Phase III clinic...